KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Amortization of Deferred Charges: 2017-2024

Historic Amortization of Deferred Charges for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $10.7 million.

  • Aquestive Therapeutics' Amortization of Deferred Charges rose 2.81% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 12.06%. This contributed to the annual value of $10.7 million for FY2024, which is 443.31% up from last year.
  • As of FY2024, Aquestive Therapeutics' Amortization of Deferred Charges stood at $10.7 million, which was up 443.31% from $2.0 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Amortization of Deferred Charges ranged from a high of $10.7 million in FY2024 and a low of $215,000 during FY2022.
  • Its 3-year average for Amortization of Deferred Charges is $4.3 million, with a median of $2.0 million in 2023.
  • As far as peak fluctuations go, Aquestive Therapeutics' Amortization of Deferred Charges tumbled by 94.24% in 2022, and later skyrocketed by 817.21% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Amortization of Deferred Charges (Yearly) stood at $2.6 million in 2020, then skyrocketed by 44.22% to $3.7 million in 2021, then plummeted by 94.24% to $215,000 in 2022, then skyrocketed by 817.21% to $2.0 million in 2023, then soared by 443.31% to $10.7 million in 2024.